US Stock MarketDetailed Quotes

IFRX InflaRx

Watchlist
  • 2.460
  • +0.060+2.50%
Close Nov 29 13:00 ET
  • 2.400
  • -0.060-2.44%
Post 14:02 ET
144.85MMarket Cap-2379P/E (TTM)

About InflaRx Company

InflaRx NV is a clinical-stage biopharmaceutical company, which engages in the discovery and development of inhibitors of the complement activation factor known as C5a and its receptor C5aR. Its primary product candidate is Vilobelimab. The company was founded by Niels Christoph Riedemann, Renfeng Guo, and Nicolas Fulpius in December 2007 and is headquartered in Jena, Germany.

Company Profile

SymbolIFRX
Company NameInflaRx
Listing DateNov 8, 2017
Issue Price15.00
Founded2007
CEOProfessor Niels Riedemann
MarketNASDAQ
Employees66
Fiscal Year Ends12-31
AddressWinzerlaer Strasse 2
CityJena
ProvinceThueringen
CountryGermany
Zip Code07745
Phone49-36-41-508180
Websitehttp://www.inflarx.de

Company Executives

  • Name
  • Position
  • Salary
  • Professor Niels Riedemann
  • Executive Director and Chief Executive Officer
  • --
  • Professor Dr. Renfeng Guo, M.D.
  • Executive Director and Chief Scientific Officer
  • --
  • Dr. Thomas Taapken
  • Chief Financial Officer
  • --
  • Dr. Camilla Chong
  • Chief Medical Officer
  • --
  • Derval O’Carroll
  • Senior Vice President and Global Head, Regulatory Affairs and Compliance
  • --
  • Nicolas Fulpius
  • Non-Executive Chairman of the Board
  • --
  • Hege Hellstrom
  • Director
  • --
  • Mark Kubler
  • Independent Director
  • --
  • Richard H. Brudnick
  • Independent Director
  • --
  • Anthony Gibney
  • Independent Director
  • --

Analysis

Analyst Rating

No Data

Price Target

No Data

Heat List
US
Overall
Symbol
Latest Price
% Chg

No Data